Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPG | P10696 | 4/20 | 0.35 |
| ▸ | PLAA | Q9Y263 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.35 |
| ▸ | ALPL | P05186 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298080 | 0.80 | ALPL (0.51) | ALPGPLAAALPLSMN1; SMN2ALPI | |
| SCHEMBL4288735 | 0.79 | FPR2 (0.40) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL13610873 | 0.78 | FPR2 (0.47) | ALDH1A1POLBKMT2A | |
| SCHEMBL13610791 | 0.77 | GRIN2B (0.39) | ALPGPLAAGRIN2BALPLSMN1; SMN2 | |
| SCHEMBL995900 | 0.74 | — | — | |
| SCHEMBL998200 | 0.71 | — | — | |
| SCHEMBL17153769 | 0.69 | ESR1 (0.57) | SMN1; SMN2POLBKMT2A | |
| SCHEMBL996895 | 0.68 | ALDH1A1 (0.63) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL9726075 | 0.68 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL5048582 | 0.68 | ALPG (0.38) | ALPGPLAAALPLSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | ALPG 1942/4885PLAA 445/4885GRIN2B 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.